Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Department of Psychiatry, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Int J Environ Res Public Health. 2022 Jun 16;19(12):7397. doi: 10.3390/ijerph19127397.
(1) Background: During the SARS-CoV-2 (COVID-19) pandemic, cannabis use increased relative to pre-pandemic levels, while forced home confinement frequently caused sleep/wake cycle disruptions, psychological distress, and maladaptive coping strategies with the consequent appearance of anxiety symptoms and their potential impact on substance use problems. (2) Aim: Long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. The present work aims to investigate the effectiveness of trazodone in optimizing the condition of people with cannabis dependence under pandemic conditions. (3) Methods: All cases with cannabis use disorder were uniformly treated with long-acting trazodone 150 mg or 300 mg/day; their craving and clinical status were monitored through appropriate psychometric scales. Side effects were recorded as they were reported by patients. We described the cases of three young patients-one man and two women-who were affected by chronic cannabis use disorder and who experienced lockdown-related psychological distress and sought psychiatric help. (4) Results: The described cases highlight that the once-a-day formulation of trazodone seems to have a therapeutic role in patients with cannabis use disorder and to guarantee tolerability and efficacy over time. No significant side effects emerged. (5) Conclusions: The use of long-acting trazodone (150 mg or 300 mg daily) has a potential benefit as monotherapy in patients with cannabis use disorder. Trazodone deserves to be studied in terms of its efficacy for cannabis use disorder.
(1) 背景：在 SARS-CoV-2（COVID-19）大流行期间，大麻的使用相对于大流行前的水平有所增加，而强制居家隔离经常导致睡眠/觉醒周期紊乱、心理困扰和适应不良的应对策略，随之出现焦虑症状及其对物质使用问题的潜在影响。(2) 目的：长效曲唑酮（每天 150 毫克或 300 毫克）作为治疗大麻使用障碍患者的单一疗法可能具有潜在益处。本研究旨在探讨曲唑酮在大流行期间优化大麻依赖患者病情的有效性。(3) 方法：所有大麻使用障碍患者均统一接受长效曲唑酮 150 毫克或 300 毫克/天治疗；通过适当的心理计量学量表监测他们的渴望和临床状况。记录患者报告的副作用。我们描述了三位年轻患者的病例，一位男性和两位女性，他们患有慢性大麻使用障碍，在封锁期间经历了心理困扰，并寻求精神科帮助。(4) 结果：所描述的病例表明，曲唑酮的每日一次制剂似乎在大麻使用障碍患者中具有治疗作用，并能保证随着时间的推移耐受性和疗效。未出现明显的副作用。(5) 结论：长效曲唑酮（每天 150 毫克或 300 毫克）作为治疗大麻使用障碍患者的单一疗法可能具有潜在益处。曲唑酮值得进一步研究其对大麻使用障碍的疗效。
